Orchard Therapeutics PLC

Orchard Therapeutics — Investor Presentation (January 2023)

27 slides from Orchard Therapeutics's investor presentation, Jan 9, 2023

  1. Slide 1: Aspiring to end devastation of genetic diseases through HSC gene therapy

    We aspire to end the devastation caused by genetic and other severe diseases through the curative potential of HSC gene therapy.

  2. Slide 2: Forward-looking Statements

    Forward-looking Statements Certain information set forth in this presentation and in statements made orally during this presentation contain “forward-looking statements”. Such forward-looking statements may be identified by words such as “anticipates,” “believes,” and “expects,” or similar expressio

  3. Slide 3: Compelling Fundamentals Driving Near and Long-term Growth

    Compelling Fundamentals Driving Near and Long-term Growth Leveraging HSC Gene Therapy Approach 1x treatment – HSC gene therapy approach offers curative potential Strong clinical track record – over 170 patients treated 100% success rate – manufacturing & releasing drug product from 80+ patients Prov

  4. Slide 4: Strong financial profile with revenue generating commercial assets

    Strong financial profile with revenue generating commercial assets 3. Estimated $144M in cash as of YE 2022 and runway expected into Q2 2024 Treating commercial early-onset MLD patients in the EU Opportunities to access additional capital and drive entry into new markets through strategic partnershi

  5. Slide 5: Summary of 2022 Accomplishments

    NBS= newborn screening * Cumulative figure referencing patients treated at CDMO Summary of 2022 Accomplishments Constructive clinical / CMC discussions; response to information and data requests Treatment of patients in the U.S. on compassionate use basis with EU CDMO manufacturing OTL-200 Regulator

  6. Slide 6: Focused Set of Corporate Goals for 2023

    Focused Set of Corporate Goals for 2023 to Drive Strategy Libmeldy revenue growth and commercial expansion BLA submission for OTL-200 (MLD) in the U.S. Initiate registrational study for OTL-203 (MPS-IH) Initiate IND-enabling activities for OTL-104 (NOD2-Crohn’s) Prudent deployment of capital to crea

  7. Slide 7: HSC Gene Therapy Offers a Highly Differentiated Approach

    Other Organ Systems Areas for potential future expansion Monocyte / Macrophage T cells B cells NK cells Megakaryocyte Erythrocyte Granulocyte Brain High area of focus GI Integration Self-renewal Literature references: Alessia Capotondo, Rita Milazzo, Letterio Salvatore Politi, Angelo Quattrini, Ales

  8. Slide 8: Focusing Where HSC Gene Therapy is Scientifically and Clinically Differentiated

    Focusing Where We Believe HSC Gene Therapy is Scientifically and Clinically Differentiated

  9. Slide 9: Strategic Long-term Growth and Value Creation with Expansion into Larger Indications

    TIME VALUE Execute and deliver on rare disease portfolio Continue to build out capabilities in HSC gene therapy across regulatory, manufacturing, commercialization and access Expand on HSC gene therapy approach for larger indications and enabling technologies Seek partnership opportunities in areas

  10. Slide 10: Strong Momentum for Libmeldy

    Libmeldy is approved in the European Union, UK, Iceland, Liechtenstein and Norway. Strong Momentum for Libmeldy Access - Reimbursement - Patient Identification - Newborn Screening U.S. & ROW European Expansion EU Launch

  11. Slide 11: Fatal genetic CNS disorder: MLD

    Fatal genetic CNS disorder Rapid and irreversible loss of motor and cognitive function In its most severe form, most children pass away within five years of symptom onset1 Age 5, pre-diagnosis Age 9, advanced disease Disease Snapshot Cognitive Age-Equivalent at each visit has been derived as follows

  12. Slide 12: Libmeldy Commercial Launch Momentum Continuing to Grow

    Access Reimbursement Secured for all eligible MLD children Germany Italy UK KEY Treatment Center (current) Treatment Center (planned) France: Reimbursed early access program secured Treatment abroad: patient from Middle East Cross border (S2) pathway: via Eastern European country Libmeldy Commercial

  13. Slide 13: Implementing Newborn Screening for MLD

    Implementing Newborn Screening for MLD KEY NBS Pilot/Study Location Some countries have more than one NBS site Newborn Screening Pilot Studies First confirmed case of MLD identified ~85,000 babies screened to date Expanding newborn screening activities throughout Europe, U.S. and the Middle East in

  14. Slide 14: OTL-200 (MLD): U.S. Regulatory Discussions Progressing

    OTL-200 (MLD): U.S. Regulatory Discussions Progressing Active, ongoing dialogue around final elements of clinical + CMC packages Constructive clinical and CMC discussions Response to information / data requests Treatment of patients in the U.S. on compassionate use basis (with EU CDMO manufacturing)

  15. Slide 15: Significant Libmeldy Platform Synergies Across Neurometabolic Pipeline

    Significant Libmeldy Platform Synergies with Potential to be Leveraged Across Neurometabolic Pipeline MPS-IH MPS-IIIA MPS-IH MPS-IIIA Research programs in larger indications & discovery pipeline MLD Treatment Sites & Referral Network Regulatory Learnings Manufacturing, Distribution, Supply Chain

  16. Slide 16: OTL-203 (MPS-IH): Interim Proof-of-concept Study Results

    SD = Standard Deviation; IQ(C) = Intelligence Quotient (Cognition); Engl J Med 2021; 385:1929-1940 DOI: 10.1056/NEJMoa2106596 OTL-203 (MPS-IH): Interim Proof-of-concept Study Results 16 | 1:100,000 live births; NBS established in some geographies, incl. U.S. Current SOC: HSCT and/or ERT as a bridgin

  17. Slide 17: OTL-203 MPS-IH Pivotal Trial Design

    OTL-203 MPS-IH Phase 3 Pivotal Trial Design Screening 1:1 Randomization Baseline Cell Harvest Conditioning OTL-203 Infusion Treatment OTL-203 20 patients HSCT 20 patients Baseline Treatment Conditioning Allogenic HSCT Follow-up Follow-up Primary Analysis at 2 Years Complication free survival (compos

  18. Slide 18: First Clinical Outcomes from OTL-201 POC Study in MPS-IIIA

    Data presented at 2022 ASH Annual Meeting First Clinical Outcomes from OTL-201 POC Study in MPS-IIIA 4 / 5 patients are demonstrating gain of cognitive skills in line with development in healthy children Demonstration of developmental skill acquisition and behavioral phenotype not typically seen in

  19. Slide 19: OTL-201 POC Study Patient 003: Marked Improvement Compared to Natural History

    Developmental Age Equivalent OTL-201 POC Study Patient 003: Marked Improvement Compared to Disease Natural History Patient 003 reached the ceiling of the Bayley scale and progressed onto the Kaufman assessment – first MPS-IIIA patient with rapidly progressive phenotype at Manchester that has complet

  20. Slide 20: Research Pipeline

    Research Pipeline Maturing the science to fuel sustainable mid- and long-term growth

  21. Slide 21: The Power of HSC Gene Therapy: Differentiation & Migration

    The Power of HSC Gene Therapy: Differentiation & Migration Alveolar macrophages Microglia Kupffer Cells Intestinal macrophages NOD2 Crohn’s FTD LUNG INTESTINE BRAIN LIVER Macrophage / Microglia T cells / B cells (regulatory T cells)

  22. Slide 22: Research Spotlight: OTL-104 for NOD2 Crohn's Disease

    Research Spotlight: OTL-104 for NOD2 Crohn’s Disease 1,2 CD prevalence estimates: Centers for Disease Control and Prevention; European Crohn’s and Colitis Organisation (ECCO) 3 NOD2: Ashton, James J et al. Clin Transl Gastroenterol. 2020 Feb Program Highlights NOD2 mutations associated with Crohn’s

  23. Slide 23: Our Platform Provides Multiple Opportunities for Business Development

    Our Platform Provides Multiple Opportunities for Business Development Immunological Diseases Oncology Neuro-degenerative Diseases Robust pipeline provides potential for additional capital, as well as expanded research capabilities, disease state knowledge, geographic footprint, commercial infrastruc

  24. Slide 24: The Journey Ahead

    The Journey Ahead Our path to becoming the global HSC gene therapy leader

  25. Slide 25: Prudent Capital Deployment Strategy

    Prudent Capital Deployment Strategy Quarterly burn rate expected to continue declining in 2023 vs. 2022 Anticipated increase in Libmeldy product sales Continued savings realized from 2022 restructuring Ongoing management of operating expenses Disciplined stewards of capital prioritizing commercializ

  26. Slide 26: Executing Toward Regulatory, Clinical and Commercial Milestones

    Executing Toward Regulatory, Clinical and Commercial Milestones Cash Position Supports Runway into Q2 2024 OTL-200: Clinical Type B meeting w/ FDA for MLD (early 2023) OTL-200: BLA submission / acceptance Regulatory Secure reimbursed treatment in at least two additional European markets Establish QT

  27. Slide 27: Strategic Anchors Represent Opportunities for Leadership in Gene Therapy

    Strategic Anchors Represent Opportunities for Leadership in Gene Therapy All based on a de-risked HSC GT scientific and clinical platform Future Potential Regulatory Approvals Leverage success in rare disease Diagnostics and Newborn Screening Develop markets Commercial Model Establish scalable busin

Orchard Therapeutics — Investor Presentation (January 2023) on 6ix